Search Results - "ДЕСТРУКЦИЯ СУСТАВОВ"

1

Academic Journal

Dynamics of Destructive Joint Changes in Juvenile Idiopathic Arthritis in Children who Received Methotrexate or Methotrexate-Tocilizumab Combination: a Cohort Study ; Динамика деструктивных изменений суставов при ювенильном идиопатическом артрите у детей, получавших метотрексат или комбинацию метотрексата и тоцилизумаба: результаты когортного исследования

Authors: Maria A. Davydova, Galina V. Santalova, Elena R. Stadler, Elena S. Gasilina, М. А. Давыдова, Г. В. Санталова, Е. Р. Стадлер, Е. С. Гасилина

Source: Current Pediatrics; Том 16, № 6 (2017); 502-508 ; Вопросы современной педиатрии; Том 16, № 6 (2017); 502-508 ; 1682-5535 ; 1682-5527

Subject Terms: модифицированный метод Шарпа, juvenile idiopathic arthritis, methotrexate, tocilizumab, joint destruction, the modified Sharpe ratio, ювенильный идиопатический артрит, метотрексат, тоцилизумаб, деструкция суставов

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/1837/752; https://vsp.spr-journal.ru/jour/article/view/1837/759; Ювенильный артрит. Клинические рекомендации для педиатров: Детская ревматология / Под ред. Баранова А.А., Алексеевой Е.И. — М.: ПедиатрЪ; 2013. — 120 с. [Yuvenil’nyi artrit. Klinicheskie rekomendatsii dlya pediatrov: Detskaya revmatologiya. Ed by Baranov A.A., Alexeeva E.I. Moscow: Paediatrician Publishers; 2013. 120 p. (In Russ).]; Алексеева Е.И., Бзарова Т.М. Алгоритм диагностики и лечения ювенильного артрита // Вопросы современной педиатрии. — 2010. — Т. 9. — № 6 — С. 78–104. [Alexeeva EI, Bzarova TM. Algorithm of diagnostics and treatment of juvenile arthritis. Current pediatrics. 2010;9(6):78–104. (In Russ).]; van Dijkhuizen EH, Wulffraat NM. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. 2014;12:51. doi:10.1186/1546-0096-12-51.; Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48(7): 1771–1774. doi:10.1002/art.11156.; Kearsley-Fleet L, McErlane F, Foster HE, et al. Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. RMD Open. 2016;2(2):e000273. doi:10.1136/rmdopen-2016-000273.; Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi:10.1002/acr.20460.; Виноградова Н.А. Влияние комбинированной терапии глюкокортикостероидами и метотрексатом на суставную деструкцию при ревматоидном артрите: Автореф. дисс. . канд. мед. наук. — М.; 2004. [Vinogradova NA. Vliyanie kombinirovannoi terapii glyukokortikosteroidami i metotreksatom na sustavnuyu destruktsiyu pri revmatoidnom artrite. [dissertation abstract] Moscоw; 2004. (In Russ).] Доступно по: http://www.dissercat.com/content/vliyaniekombinirovannoi-terapii- glyukokortikosteroidami-i-metotreksatomna-sustavnuyu-destr. Ссылка активна на 12.11.2017.; Wallace CA, Sherry DD, Mellins ED, Aiken RP. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol. 1993;20(1):118–122.; Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol. 1995;13(1):113–118.; Harel L, Wagner-Weiner L, Poznanski AK, et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. 1993;36(10):1370–1374. doi:10.1002/art.1780361007.; Prieur AM, Malleson PN, Kimura Y. Systemic arthritis. In: Szer LS, Kimura Y, Malleson PN, Southwood TR, editors. Arthritis in children and adolescents: juvenile idiopathic arthritis. NY, USA: Oxford University Press; 2006. pp. 210–222.; Szer LS, Kimura Y, Malleson PN, Southwood TR, editors. Arthritis in children and adolescents: juvenile idiopathic arthritis. NY, USA: Oxford University Press; 2006. 456 p.; Вакуленко О.Ю., Кричевская О.А., Эрдес Ш.Ф. Про грессирование деструкции суставов у больных ревматоидным артритом // Научно-практическая ревматология. — 2011. — № 3 — С. 69–74. [Vakulenko OYu, Krichevskaya OA, Erdes ShF. Progression of joint destruction in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2011; (3):69–74. (In Russ).] doi:10.14412/1995-4484-2011-575.; Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–1117. doi:10.1136/annrheumdis-2014-205351.; Родионовская С.Р., Никишина И.П. «Эра метотрексата» в детской ревматологии // Вопросы современной педиатрии. — 2006. — Т. 5. — № 3 — С. 31–39. [ Rodionovskaya SR, Nikishina IP. «Methotrexate era» in children rheumatology. Current pediatrics. 2006;5(3):31–39. (In Russ).]; Матвеева Н.В., Манеров Ф.К., Котович М.М. Применение высоких доз метотрексата в лечении системных форм ревматоидного артрита у детей // Мать и дитя в Кузбасе. — 2005. — № 1 — С. 16–19. [Matveeva NV, Manerov FK, Kotovich MM. Primenenie vysokikh doz metotreksata v lechenii sistemnykh form revmatoidnogo artrita u detei. Mat’ i ditya v Kuzbase. 2005;(1): 16–19. (In Russ).]; Матюнова А.Е. Факторы риска деструктивных повреждений суставов у детей с ювенильным идиопатическим артритом: Автореф. дисс. . канд. мед. наук. — Новосибирск; 2013. [Matyunova AE. Faktory riska destruktivnykh povrezhdenii sustavov u detei s yuvenil’nym idiopaticheskim artritom. [dissertation abstract] Novosibirsk; 2013. (In Russ).] Доступно по: http://medical-diss.com/medicina/faktoryriska-destruktivnyh- povrezhdeniy-sustavov-u-detey-s-yuvenilnymidiopaticheskim-artritom. Ссылка активна на 12.11.2017.; Кричевская О.А., Горячев Д.В., Смирнов А.В., Эрдес Ш.Ф. Некоторые методы оценки прогрессирования рентгенологических проявлений ревматоидного артрита // Научно- практическая ревматология. — 2007. — Т. 45. — № 2 — С. 56–63. [Krichevskaya OA, Goryachev DV, Smirnov AV, Erdes SF. Methods of rheumatoid arthritis radiological progression assessment. Rheumatology Science and Practice. 2007;45(2):56–63. (In Russ).] doi:10.14412/1995-4484-2007-839.; rlsnet.ru [интернет]. Справочник «Электронная энциклопедия лекарств». Серия РЛС. 2017 [доступ от 21.11.2017]. [Spravochnik «Elektronnaya entsiklopediya lekarstv». Seriya RLS. 2017 (In Russ).] Доступ по ссылке https://www.rlsnet.ru/.; Ravelli A. The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials. J Rheumatol. 2008;35(4):553–557.; Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol. 2004;31(2):390–392.; Насонов Е.Л., Насонова В.А. Ревматология. Национальное руководство. — М.: ГЭОТАР-Медиа; 2008. 282 с. [Nasonov EL, Nasonova VA. Revmatologiya. Natsional’noe rukovodstvo. Moscow: Geotar-Media; 2008. 282 p. (In Russ).]; Giancane G, Consolaro A, Lanni S, et al. Radiographic damage in hands and wrists of patients with juvenile idiopathic arthritis after 29 years of disease duration. Pediatr Rheumatol Online J. 2017;15(1):20. doi:10.1186/s12969-017-0151-7.; Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum. 2007;56(9):3087–3095. doi:10.1002/art.22835.; Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272. doi:10.1186/s13075-016-1170-3.; Shepherd J, Cooper K, Harris P, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222. doi:10.3310/hta20340.; Brennan P, Harrison В, Barrett Е. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ. 1996; 313(7055):471–476. doi:10.1136/bmj.313.7055.471.

Availability: https://vsp.spr-journal.ru/jour/article/view/1837
https://doi.org/10.15690/vsp.v16i6.1823

View record from BASE

2

Academic Journal

AN ASSOCIATION OF CYTOKINE LEVELS WITH DISEASE ACTIVITY, AUTOANTIBODY LEVELS, AND JOINT DESTRUCTIVE CHANGES IN EARLY RHEUMATOID ARTHRITIS ; Связь уровней цитокинов с активностью заболевания, уровнем аутоантител и деструктивными изменениями суставов при раннем ревматоидном артрите

Authors: A. S. Avdeeva, A. A. Novikov, E. N. Aleksandrova, D. E. Karateev, A. V. Smirnov, E. L. Luchikhina, E. L. Nasonov, А. С. Авдеева, А. А. Новиков, Е. Н. Александрова, Д. Е. Каратеев, А. В. Смирнов, Е. Л. Лучихина, Е. Л. Насонов

Source: Rheumatology Science and Practice; Vol 53, No 4 (2015); 385-390 ; Научно-практическая ревматология; Vol 53, No 4 (2015); 385-390 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20154

Subject Terms: цитокиновый профиль, autoantibodies, joint destruction, cytokine profile, аутоантитела, деструкция суставов

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2109/1337; Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит В кн.: Ревматология: Национальное руководство. Под ред. ЕЛ Насонова, ВА Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova A, editors. Revmatologiya: Natsional'noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290–331].; Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010].; Choy E. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:510–8.; Firestein G. Evolving concepts of rheumatoid arthritis. Nature. 2003;344:907–16. doi:10.1038/nature01661; McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42. doi:10.1038/nri2094; Dayer J, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985;162(6):2163–8. doi:10.1084/jem.162.6.2163; Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717–25. doi:10.1056/NEJM199606273342607; Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004:13(4):193–222. doi:10.1111/j.0906-6705.2004.00205.x; Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol. 2003 SepOct;21(5):392–7. doi:10.1016/j.clindermatol.2003.08.015; Taha A, Grant V, Kelly R. Urinalysis for interleukin-8 in the noninvasive diagnosis of acute and chronic inflammatory diseases. Postgrad Med J. 2003;79(929):159–63. doi:10.1136/pmj.79.929.159; Rothe L, Collin-Osdoby P, Chen Y, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139(10):4353–63.; Romano M, Polentarutti N, Fruscella P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6;315–25. doi:10.1016/S1074-7613(00)80334-9; Lally F, Smith E, Filer A, et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005;52:3460–9. doi:10.1002/art.21394; Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74. doi:10.1016/S0140-6736(07)60784-3; Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002;4(Suppl. 3):81–90. doi:10.1186/ar575; Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res Ther. 2007;9:203. doi:10.1186/ar2110; Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1–7. doi:10.1016/S8756- 3282(02)00915-8; Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521–9. doi:10.1002/art.11143; Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307–10. doi:10.1016/S0092-8674(00)81109-5; Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi:10.1146/annurev.immunol.14.1.397; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. doi:10.1136/ard.2010.138461; Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].; Van der Heijde D, Boers M, Lassere M. Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol. 1999;26:726–30.; Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exper Rheumatol. 2007;25:584–92.; Hueber W, Tomooka B, Zhao X, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis. 2007;66;712–9. doi:10.1136/ard.2006.054924; Yellin M, Paliienko I Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of mdx-1100, a fully human anti-cxcl10 monoclonal antibody, in combination with methotrexate in patients with rheumatoidarthritis. Arthritis Rheum. 2012;64:1730–9. doi:10.1002/art.34330; Astry B, Venkatesha S, Moudgil K. Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis. Indian J Med Res. 2013;138:717–31.; Каратеев ДЕ. Ангиогенез при ревматоидном артрите. Вестник РАМН. 2003;7:47–51 [Karateev DE. Angiogenesis in rheumatoid arthritis. Vestnik RAMN. 2003;7:47–51 (In Russ.)].; Marrelli A, Cipriani P, Liakouli V, et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev. 2011;10:595–8. doi:10.1016/j.autrev.2011.04.020; Paleolog EM. The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol. 2009;90:249–61. doi:10.1111/j.1365-2613.2009.00640.x; Lu Q, Lu S, Gao X, et al. Norisoboldine, an alkaloid compound isolated from Radix linderae, inhibits synovial angiogenesis in adjuvant-induced arthritis rats by moderating Notch1 pathwayrelated endothelial tip cell phenotype. Exp Biol Med (Maywood). 2012;237:919–32. doi:10.1258/ebm.2012.011416; Tanaka K, Morii T, Weissbach L, et al. Treatment of collageninduced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. J Orthop Sci. 2011;16:443–50. doi:10.1007/s00776-011-0091-x; Yoo SA, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNFalpha and IL-6 by human monocytes. J Immunol. 2005;174:5846–55. doi:10.4049/jimmunol.174.9.5846; Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis. 2008;11:121–40. doi:10.1007/s10456-008-9107-3; Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006;21:557–66.; Ballara S, Taylor P, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001;44:2055–64. doi:10.1002/1529-0131(200109)44:93.0.CO;2-2; Clavel G, Bessis N, Lemeiter D. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol. 2007;124:158–64. doi:10.1016/j.clim.2007.04.014; Knudsen L, Ostergaard M, Baslund B, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol. 2006;35:489–95. doi:10.1080/03009740600904300; Kurosaka D, Hirai K, Nishioka M, et. al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol. 2010;37:6. doi:10.3899/jrheum.090941; Kokkonen H, Soderstrom I, Rocklov J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383–91. doi:10.1002/art.27186; Sokolove J, Bromberg R, Deane K, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi:10.1371/journal.pone.0035296; Eastman PS, Manning WC, Qureshi F, et al. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal. 2012;70:415–24. doi:10.1016/j.jpba.2012.06.003; Raza K, Falciani F, Curnow S, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005;7(4):784–95. doi:10.1186/ar1733

Availability: https://rsp.mediar-press.net/rsp/article/view/2109
https://doi.org/10.14412/1995-4484-2015-385-390

View record from BASE

3

Academic Journal

Bone destruction in rheumatoid arthritis: role of autoantibodies ; Деструкция костной ткани при ревматоидном артрите: роль аутоантител

Authors: Anastasia Sergeyevna Avdeyeva, E N Aleksandrova, A A Novikov, A V Smirnov, M V Cherkasova, E L Nasonov, Елена Николаевна Александрова, А. А. Новиков, А. В. Смирнов, М. В. Черкасова, Евгений Львович Насонов

Source: Rheumatology Science and Practice; Vol 51, No 3 (2013); 267-271 ; Научно-практическая ревматология; Vol 51, No 3 (2013); 267-271 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-3

Subject Terms: маркеры воспаления, joint destruction, IgM rheumatoid factor, anti-cyclic citrullinated peptide antibodies, anti-modified citrullinated vimentin antibodies, inflammatory markers, деструкция суставов, IgM ревматоидный фактор, антитела к циклическому цитруллинированному пептиду, антитела к модифицированному цитруллинированному виментину

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1315/974; Новиков А.А., Александрова Е.Н., Черкасова М.В. и др. Современные методы лабораторной диагностики ревматоидного артрита. Науч-практич ревматол 2010;1:31—45. Aggarwal R., Liao K., Nair R. et al. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthr Rheum 2009;61:1472—83. Song Y.W., Kang E.H. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010;103:139—46. Meyer O., Labarre C., Dougados M. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120—6. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009;373:659—72. Ursum J., Bos W.H., van de Stadt R.J. et al. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence o two distinct autoantibody systems. Arthr Res Ther 2009;11:7. Valesini G., Alessandri C. Anticitrullinate antibodies and rheumatoid factors: two distinct autoantibody systems. Arthr Res Ther 2009;11:125. Riedemann J.P., Munoz S., Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis — a systematic review. Clin Exp Rheumatol 2005;2:69—76. Turesson C., Jacobsson L.T., Sturfelt G. et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66:59—64. Machold K.P., Stamm T.A., Nell V.P. et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342—9. Новиков А.А., Александрова Е.Н., Каратеев Д.Е. и др. Диагностическое значение антител к модифицированному циклическому виментину при раннем ревматоидном артрите. Клин лаб диагн 2008;8:27—9. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthr Res Ther 2007;9:203. Gravallese E.M., Manning C., Tsay A. et al. Synovial tissue in rheumatoid arthritis is asource of osteoclast differentiation factor. Arthr Rheum 2000;43:250—8. Shigeyama Y., Pap T., Kunzler P. et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthr Rheum 2000;43:2523—30. Sato K., Suematsu A., Okamoto K. et al. Th17 functions as an osteoclastogenic T helper cell subset that links T cell activation and bone destruction. J Exp Med 2006;2203:2673—82. Seitz M., Loetscher P., Fey M.F. et al. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 1994;33:613—9. Stolina M., Adamu S., Ominsky M. et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005;20:1756—65. Lam J., Takeshita S., Barker J.E. et al. TNF-alpha induces osteo-clastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481—8. Lubberts E., van den Bersselaar L., Oppers-Walgreen B. et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655—62. Wei S., Kitaura H., Zhou P. et al. Teitelbaum SL: IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282—90. Azuma Y., Kaji K., Katogi R. et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858—64. Matsumoto M., Sudo T., Maruyama M. et al. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000;486:23—8. Harre U., Georgess, D., Bang H. et al. Induction of osteoclastoge-nesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122:1791—802. Harre U., Georgess D., Axmann R. et al. Anti-citrullinated protein antibodies directly induce bone loss in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 3):59. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743—5. Смирнов А.В. Атлас рентгенологической диагностики ревматоидного артрита. М.: ИМА-ПРЕСС, 2009. Syversen S., Goll G., van der Heijde D. et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis. 2010;69:345—51. Mathsson L., Mullazehi M., Wick M. et al. Antibodies against cit-rullinated vimentin in rheumatoid arthritis. Arthr Rheum 2008;58:36—45. Mansour H., Metwaly K., Hassan I. et al. Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clin Med: Arthr Musculoskelet Dis 2010;3:33—42. Boire G., Gosette P., Combe B. et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients witch recent-onset polyarthritis. Arthr Res Ther 2005;7:529—603. Vossenaar E.R., Despres N., Lapointe E. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthr Res Ther 2004;6:142—50. Welsing P., Landewe R., van Riel P. et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthr Rheum 2004;50:2082—93. Plant M.J., Williams A.L., O'Sullivan M.M. et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthr Rheum 2000;43:1473—7. Van Leeuwen M.A., van Rijswijk M.H., van der Heijde D.M. et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32:9—13. Van der Heide A., Remme C.A., Hofman D.M. et al. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthr Rheum 1995;38:1466—74. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003;111:1805—12. Combe B., Dougados M., Goupille P. et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthr Rheum 2001;44:1736—43. Bang H., Lü thke K., Gauliard A. et al. Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006;65(Suppl II):144. Roland P., Mignot S., Bruns A. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthr Res Ther 2008;10:142.

Availability: https://rsp.mediar-press.net/rsp/article/view/1315
https://doi.org/10.14412/1995-4484-2013-1499

View record from BASE

4

Academic Journal